Synairgen plc (LON:SNG) insider Richard J. Marsden purchased 156,250 shares of the stock in a transaction that occurred on Friday, October 12th. The shares were bought at an average cost of GBX 16 ($0.21) per share, for a total transaction of £25,000 ($32,666.93).
LON SNG opened at GBX 16.25 ($0.21) on Friday. Synairgen plc has a 52-week low of GBX 6.88 ($0.09) and a 52-week high of GBX 32 ($0.42).
Separately, FinnCap reissued a “corporate” rating on shares of Synairgen in a report on Thursday, June 28th.
Synairgen plc discovers and develops drugs for respiratory diseases. It develops inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment or prevention of asthma exacerbations caused by the common cold; IFN-ß that is in Phase-I clinical trial for the treatment or prevention of chronic obstructive pulmonary disease exacerbations caused by the common cold; and LOXL2 inhibitor, which is in Phase I clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).
Further Reading: Stock Symbols Definition, Examples, Lookup
Receive News & Ratings for Synairgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synairgen and related companies with MarketBeat.com's FREE daily email newsletter.